Replies to post #445 on Contrafect Corp (CFRX)

[drkazmd65]

They have a few other potential anti-bacterial products in their pipelines, but none were beyond preclinical testing other than Exebacase. And Exebacase just got stopped in Phase III testing - which is why stock prices just dropped like a stone.

Here's their described pipeline page
https://www.contrafect.com/pipeline/overview

Realistically - each of those other potential anti-bacterial products are years from being revenue generators.

If there is not some underlying positive angle that the company can redirect Exebacase toward, it's going to be a while before this company takes off and generates any revenue stream.